Novel anticoagulants in atrial fibrillation: A primer for the primary physician

Martina Mookadam, Fadi E. Shamoun, Farouk Mookadam

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Atrial fibrillation is a common arrhythmia encountered in clinical practice. The prevalence increases with age. A devastating complication of atrial fibrillation is cardioembolic stroke with central nervous system sequelae. Based on stroke risk scores (CHADS and CHA<inf>2</inf>DS<inf>2</inf>VASc) and bleeding risk (HAS-BLED), the optimal use of anticoagulation in atrial fibrillation is feasible. Warfarin is a proven medication for this specific indication but requires frequent monitoring and dose adjustments, and it has multiple food, drug, and disease-state interactions. In addition, management of anticoagulation during the perioperative period may be challenging. In this regard, novel oral anticoagulants (NOACs) have shown promise in the shift toward the "ideal" anticoagulant therapy, in that fixed dosing is the norm, drug interactions are few, food interactions are absent, onset is fairly immediate and offset predictable, and, in the majority of patients, therapeutic monitoring is not required. This article provides a review of recent published trials of the use of NOACs in atrial fibrillation. Practical points on indications, contraindications, mechanism of action, interactions, and perioperative management tips are discussed with a view toward the safe and effective use of these new medications. When patients are transitioned between different anticoagulant medications, the risks of thrombosis and bleeding need to be considered. When switching from warfarin to a NOAC, the NOAC can be started once the international normalized ratio is ≤2.0.

Original languageEnglish (US)
Pages (from-to)510-522
Number of pages13
JournalJournal of the American Board of Family Medicine
Volume28
Issue number4
DOIs
StatePublished - Jul 1 2015

Fingerprint

Anticoagulants
Atrial Fibrillation
Physicians
Warfarin
Stroke
Food-Drug Interactions
Hemorrhage
Perioperative Period
International Normalized Ratio
Physiologic Monitoring
Drug Interactions
Cardiac Arrhythmias
Thrombosis
Central Nervous System
Food
Therapeutics
Pharmaceutical Preparations

Keywords

  • Anticoagulants
  • Arrhythmia
  • Atrial fibrillation
  • Pharmacotherapy
  • Preventive medicine
  • Stroke

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Family Practice

Cite this

Novel anticoagulants in atrial fibrillation : A primer for the primary physician. / Mookadam, Martina; Shamoun, Fadi E.; Mookadam, Farouk.

In: Journal of the American Board of Family Medicine, Vol. 28, No. 4, 01.07.2015, p. 510-522.

Research output: Contribution to journalArticle

Mookadam, Martina ; Shamoun, Fadi E. ; Mookadam, Farouk. / Novel anticoagulants in atrial fibrillation : A primer for the primary physician. In: Journal of the American Board of Family Medicine. 2015 ; Vol. 28, No. 4. pp. 510-522.
@article{48fb3c49508a4f759e78e8ba92fb2a30,
title = "Novel anticoagulants in atrial fibrillation: A primer for the primary physician",
abstract = "Atrial fibrillation is a common arrhythmia encountered in clinical practice. The prevalence increases with age. A devastating complication of atrial fibrillation is cardioembolic stroke with central nervous system sequelae. Based on stroke risk scores (CHADS and CHA2DS2VASc) and bleeding risk (HAS-BLED), the optimal use of anticoagulation in atrial fibrillation is feasible. Warfarin is a proven medication for this specific indication but requires frequent monitoring and dose adjustments, and it has multiple food, drug, and disease-state interactions. In addition, management of anticoagulation during the perioperative period may be challenging. In this regard, novel oral anticoagulants (NOACs) have shown promise in the shift toward the {"}ideal{"} anticoagulant therapy, in that fixed dosing is the norm, drug interactions are few, food interactions are absent, onset is fairly immediate and offset predictable, and, in the majority of patients, therapeutic monitoring is not required. This article provides a review of recent published trials of the use of NOACs in atrial fibrillation. Practical points on indications, contraindications, mechanism of action, interactions, and perioperative management tips are discussed with a view toward the safe and effective use of these new medications. When patients are transitioned between different anticoagulant medications, the risks of thrombosis and bleeding need to be considered. When switching from warfarin to a NOAC, the NOAC can be started once the international normalized ratio is ≤2.0.",
keywords = "Anticoagulants, Arrhythmia, Atrial fibrillation, Pharmacotherapy, Preventive medicine, Stroke",
author = "Martina Mookadam and Shamoun, {Fadi E.} and Farouk Mookadam",
year = "2015",
month = "7",
day = "1",
doi = "10.3122/jabfm.2015.04.140297",
language = "English (US)",
volume = "28",
pages = "510--522",
journal = "Journal of the American Board of Family Medicine",
issn = "1557-2625",
publisher = "American Board of Family Medicine",
number = "4",

}

TY - JOUR

T1 - Novel anticoagulants in atrial fibrillation

T2 - A primer for the primary physician

AU - Mookadam, Martina

AU - Shamoun, Fadi E.

AU - Mookadam, Farouk

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Atrial fibrillation is a common arrhythmia encountered in clinical practice. The prevalence increases with age. A devastating complication of atrial fibrillation is cardioembolic stroke with central nervous system sequelae. Based on stroke risk scores (CHADS and CHA2DS2VASc) and bleeding risk (HAS-BLED), the optimal use of anticoagulation in atrial fibrillation is feasible. Warfarin is a proven medication for this specific indication but requires frequent monitoring and dose adjustments, and it has multiple food, drug, and disease-state interactions. In addition, management of anticoagulation during the perioperative period may be challenging. In this regard, novel oral anticoagulants (NOACs) have shown promise in the shift toward the "ideal" anticoagulant therapy, in that fixed dosing is the norm, drug interactions are few, food interactions are absent, onset is fairly immediate and offset predictable, and, in the majority of patients, therapeutic monitoring is not required. This article provides a review of recent published trials of the use of NOACs in atrial fibrillation. Practical points on indications, contraindications, mechanism of action, interactions, and perioperative management tips are discussed with a view toward the safe and effective use of these new medications. When patients are transitioned between different anticoagulant medications, the risks of thrombosis and bleeding need to be considered. When switching from warfarin to a NOAC, the NOAC can be started once the international normalized ratio is ≤2.0.

AB - Atrial fibrillation is a common arrhythmia encountered in clinical practice. The prevalence increases with age. A devastating complication of atrial fibrillation is cardioembolic stroke with central nervous system sequelae. Based on stroke risk scores (CHADS and CHA2DS2VASc) and bleeding risk (HAS-BLED), the optimal use of anticoagulation in atrial fibrillation is feasible. Warfarin is a proven medication for this specific indication but requires frequent monitoring and dose adjustments, and it has multiple food, drug, and disease-state interactions. In addition, management of anticoagulation during the perioperative period may be challenging. In this regard, novel oral anticoagulants (NOACs) have shown promise in the shift toward the "ideal" anticoagulant therapy, in that fixed dosing is the norm, drug interactions are few, food interactions are absent, onset is fairly immediate and offset predictable, and, in the majority of patients, therapeutic monitoring is not required. This article provides a review of recent published trials of the use of NOACs in atrial fibrillation. Practical points on indications, contraindications, mechanism of action, interactions, and perioperative management tips are discussed with a view toward the safe and effective use of these new medications. When patients are transitioned between different anticoagulant medications, the risks of thrombosis and bleeding need to be considered. When switching from warfarin to a NOAC, the NOAC can be started once the international normalized ratio is ≤2.0.

KW - Anticoagulants

KW - Arrhythmia

KW - Atrial fibrillation

KW - Pharmacotherapy

KW - Preventive medicine

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=84937155899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937155899&partnerID=8YFLogxK

U2 - 10.3122/jabfm.2015.04.140297

DO - 10.3122/jabfm.2015.04.140297

M3 - Article

C2 - 26152444

AN - SCOPUS:84937155899

VL - 28

SP - 510

EP - 522

JO - Journal of the American Board of Family Medicine

JF - Journal of the American Board of Family Medicine

SN - 1557-2625

IS - 4

ER -